Vijay Patil

16PUBLICATIONS
105CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jun 17, 2026
Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS).

|Apr 23, 2026
Low-Dose Versus Standard-Dose Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multicenter Randomized Phase III Trial.

|Mar 11, 2026
Circulating CAR-T Impostors: Monocyte-Like Cells Marking Successful MRD-Negative Remission

Bilal Kazi, Vijay Patil, Imaan Rumani

|Jan 28, 2026
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII).

Vanita Noronha, Vijay Patil, Nandini Menon

|Jul 17, 2025
Comprehensive Genomic Profiling of Anaplastic Thyroid Cancer Identifies Alterations in THRA, a Potential Modifier of Cellular Plasticity.

Vaishakhi Trivedi, Vanita Noronha, Munita Bal

|May 22, 2025
Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study).

Akhil Kapoor, Anuj Gupta, Bipinesh Sansar

Pageof 3

Frequent Collaborators

15 joint publications

Vanita Noronha

15 joint publications

Kumar Prabhash

7 joint publications

Nandini Menon

5 joint publications

Pratik Chandrani